<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">Reactivation of chronic viral infections, such as hepatitis B and cytomegalovirus, is a rare yet well-reported adverse effect of rituximab.
 <xref rid="bib59" ref-type="bibr">
  <sup>59</sup>
 </xref> Other viral illnesses, such as URIs and nasopharyngitis, are frequently reported, but clinical trial data in rheumatoid arthritis suggest similar overall rates of infections when rituximab is compared with methotrexate plus placebo.
 <xref rid="bib60" ref-type="bibr">
  <sup>60</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib61" ref-type="bibr">
  <sup>61</sup>
 </xref> Long-term observational studies also show that this risk remains stable with repeated infusions.
 <xref rid="bib62" ref-type="bibr">
  <sup>62</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib63" ref-type="bibr">
  <sup>63</sup>
 </xref> Data in the dermatologic literature are limited, but a randomized controlled trial in pemphigus vulgaris showed a similar rate of infections in the rituximab plus short-term steroid group compared with the steroid-only group.
 <xref rid="bib64" ref-type="bibr">
  <sup>64</sup>
 </xref> However, it is worth noting that the rituximab group had lower cumulative exposure to prednisone.
</p>
